Primary aldosteronism as a systemic endocrine tumor disease: a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance
- 1Department of Urology, First Affiliated Hospital of Gannan Medical University
Abstract
Primary aldosteronism (PA) is a systemic endocrine tumor disease driven by somatic-mutation-defined aldosterone-producing lesions. In most unilateral cases, adrenalectomy achieves biochemical cure and restores mortality to that of the general population. However, diagnostic delay, limited access to adrenal venous sampling (AVS) and specialized surgery, and bilateral or non-operable disease mean that many patients require lifelong pharmacological therapy and structured surveillance. This review proposes a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance around four pillars: (1) early and expanded screening, stratified by pretest probability and severity; (2) precision subtyping, with surgical candidacy and patient preference as the first decision node, integrated with probability-based pathways, Primary Aldosteronism Severity Classification (PASC) grading, molecular and genetic subtyping, and cortisol co-secretion screening; (3) targeted source elimination (adrenalectomy) or mineralocorticoid receptor (MR) blockade, with plasma renin reactivation proposed as a candidate pharmacodynamic marker rather than a validated endpoint; and (4) structured long-term surveillance, with basic assessments universal and advanced imaging reserved for high-risk patients or research protocols. For each pillar, we distinguish guideline-based recommendations from expert consensus and research-oriented components, and identify key evidence gaps. We critically appraise 2025–2026 guidelines and emerging evidence on molecular imaging, patient-reported outcomes, and novel agents. The framework translates pathophysiological insights into an actionable, organ-protection-centered pathway while remaining explicit about what is known, assumed, and still unproven; several components—renin-guided MR antagonist titration, AVS-bypass strategies, and advanced follow-up imaging—remain hypothesis-generating and require prospective validation.
Related
- Surgical decision-making and referral patterns for adrenal vein sampling in primary aldosteronism: a national survey of endocrine surgeons
- Non-diabetic endocrine neuropathies: A practical approach to diagnosis and clinical evaluation
- Impact of Statin and Aspirin Use on Dementia Diagnosis Stratified by Cardiovascular Risk
- Hypertension care cascade among adults in a Malaysian health surveillance cohort: a longitudinal evaluation of screening, diagnosis, treatment, and control
- Surveillance Mammography and Second Primary Breast Cancer Diagnosis Among Older Women With a History of Breast Cancer
BibTeX
@article{gong2026primary,
title = {{Primary aldosteronism as a systemic endocrine tumor disease: a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance}},
author = {Jianxin Gong and Yue Wang and Jiaqiang Gui and Haiye Fan and Xiaofeng Zou and Tianpeng Xie},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.2023718},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.2023718/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Primary aldosteronism as a systemic endocrine tumor disease: a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance
AU - Jianxin Gong
AU - Yue Wang
AU - Jiaqiang Gui
AU - Haiye Fan
AU - Xiaofeng Zou
AU - Tianpeng Xie
PY - 2026
DA - 2026/11/16
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.2023718
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.2023718/full
AB - Primary aldosteronism (PA) is a systemic endocrine tumor disease driven by somatic-mutation-defined aldosterone-producing lesions. In most unilateral cases, adrenalectomy achieves biochemical cure and restores mortality to that of the general population. However, diagnostic delay, limited access to adrenal venous sampling (AVS) and specialized surgery, and bilateral or non-operable disease mean that many patients require lifelong pharmacological therapy and structured surveillance. This review proposes a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance around four pillars: (1) early and expanded screening, stratified by pretest probability and severity; (2) precision subtyping, with surgical candidacy and patient preference as the first decision node, integrated with probability-based pathways, Primary Aldosteronism Severity Classification (PASC) grading, molecular and genetic subtyping, and cortisol co-secretion screening; (3) targeted source elimination (adrenalectomy) or mineralocorticoid receptor (MR) blockade, with plasma renin reactivation proposed as a candidate pharmacodynamic marker rather than a validated endpoint; and (4) structured long-term surveillance, with basic assessments universal and advanced imaging reserved for high-risk patients or research protocols. For each pillar, we distinguish guideline-based recommendations from expert consensus and research-oriented components, and identify key evidence gaps. We critically appraise 2025–2026 guidelines and emerging evidence on molecular imaging, patient-reported outcomes, and novel agents. The framework translates pathophysiological insights into an actionable, organ-protection-centered pathway while remaining explicit about what is known, assumed, and still unproven; several components—renin-guided MR antagonist titration, AVS-bypass strategies, and advanced follow-up imaging—remain hypothesis-generating and require prospective validation.
SN - 1664-2392
ER -